HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Generation and testing of engineered multimeric Fabs of trastuzumab.

Abstract
Recombinant antibodies fragments in several new formats are routinely investigated and used in diagnostic and therapeutic applications as anti-cancers molecules. New antibody formats are generated to compensate the need for multispecificity and site-specific introduction of fluorescent dyes, cytotoxic payloads or for generating semisynthetic multimeric molecules. Fabs of trastuzumab bearing transglutaminase (MTG) reactive sites were generated by periplasmic expression in E. coli and purified. Multimeric Fabs were generated by either disulfide bridge formation or by using MTG-sensitive peptide linkers. Binding to receptor was assessed by ELISA and SPR methods. Internalization and growth inhibition assays were performed on BT-474 and SKBR3 Her2+ cells. Fabs were successfully produced and dimerized or trimerized using MTG and suitably designed peptide linkers. Site-specific derivatizations with fluorophores were similarly achieved. The monomeric, dimeric and trimeric variants bind the receptor with affinities similar or superior to the full antibody. Fab and Fab2 are rapidly internalized in Her2+ cells and exhibit growth inhibition abilities similar to the full antibody. Altogether, the data show that the recombinant Fabs can be produced in E. coli and converted into multimeric variants by MTG-based bioconjugation. Similar approaches are extendable to the introduction of cytotoxic payloads for the generation of novel Antibody Drug Conjugates.
AuthorsFabio Selis, Annamaria Sandomenico, Maria Cantile, Riccardo Sanna, Luisa Calvanese, Lucia Falcigno, Paolo Dell'Omo, Andrea Esperti, Sandro De Falco, Annalia Focà, Andrea Caporale, Emanuela Iaccarino, Emanuela Truppo, Silvia Scaramuzza, Giancarlo Tonon, Menotti Ruvo
JournalInternational journal of biological macromolecules (Int J Biol Macromol) Vol. 164 Pg. 4516-4531 (Dec 01 2020) ISSN: 1879-0003 [Electronic] Netherlands
PMID32941911 (Publication Type: Journal Article)
CopyrightCopyright © 2020 Elsevier B.V. All rights reserved.
Chemical References
  • DNA, Complementary
  • Fluorescent Dyes
  • Immunoconjugates
  • Immunoglobulin Fab Fragments
  • Peptide Fragments
  • Recombinant Proteins
  • Cystine
  • Transglutaminases
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
Topics
  • Amino Acid Sequence
  • Breast Neoplasms (pathology)
  • Carcinoma (pathology)
  • Cell Line, Tumor
  • Cystine (chemistry)
  • DNA, Complementary (genetics)
  • Drug Design
  • Drug Screening Assays, Antitumor
  • Escherichia coli
  • Female
  • Fluorescent Dyes
  • Humans
  • Immunoconjugates (chemistry, immunology)
  • Immunoglobulin Fab Fragments (chemistry, genetics, immunology)
  • Models, Molecular
  • Peptide Fragments (chemical synthesis)
  • Protein Conformation
  • Protein Engineering
  • Protein Multimerization
  • Receptor, ErbB-2 (immunology)
  • Recombinant Proteins (chemistry, genetics, immunology)
  • Surface Plasmon Resonance
  • Transglutaminases (immunology)
  • Trastuzumab (chemistry, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: